SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
- PMID: 36820593
- PMCID: PMC9907906
- DOI: 10.1097/MD.0000000000032795
SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
Abstract
Coronavirus disease 2019 (COVID-19) is a major global health concern. In contrast to adults, the course of the disease has been observed to be mild or even asymptomatic in children. It is therefore both clinically and epidemiologically important to measure the seroprevalence in children and adolescents to discern the overall morbidity of the disease and to compare these findings with similar data collected globally. We conducted a cross-sectional study between March and July of 2022 at the Children Clinical University Hospital in Riga, Latvia, to evaluate the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants aged 0 to 18 years were enrolled during hospitalization for reasons other than COVID-19. The levels of SARS-CoV-2 spike protein and nucleocapsid antibodies were measured in blood samples. The possibility of transplacental antibody transport was evaluated by directly interviewing the mothers of participants aged 18 months and younger. Various demographic and epidemiological risk factors and their association with seroprevalence were analyzed. Positive SARS-CoV-2 nucleocapsid antibodies were designated the main criterion for seropositivity. Of 200 enrolled children, 173 were found to be seropositive, resulting in an overall seroprevalence of 86.5%. The highest seroprevalence was detected in children and adolescents aged 12 to 18 years. With the progression of the COVID-19 pandemic, the seroprevalence in children has increased significantly. We found that almost 1-third of seropositive children in our study population were unaware of being previously infected with SARS-CoV-2 due to an asymptomatic course of the disease. Our study findings pertaining to high seropositivity among children and adolescents might be beneficial for public authorities to adapt epidemiological strategies and prevention measures. The high seroprevalence rate reported here and in many other populations around the world suggests that COVID-19 will likely become one of the many seasonal viral infections.
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures
References
-
- World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-genera.... [access date September 4, 2022]. Published March 11, 2020.
-
- Centre for Disease Prevention and Control (SPKC). Statistics of Covid-19 [Covid-19 statistika]. Available at: https://www.spkc.gov.lv/lv/covid-19-statistika. [access date September 4, 2022]. Published February 3, 2021.
-
- Ministry of Health of the Republic of Latvia. Actualities about Covid-19 [Aktualitātes par Covid-19]. Available at: https://www.vm.gov.lv/sites/vm/files/data-content/kopsavilkums_24h_covid.... [access date September 4, 2022]. Published March 3, 2020.
-
- Valdez AC, Iftekhar EN, Oliu-Barton M, et al. Europe must come together to confront omicron. BMJ. 2022;376:o90. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
